8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Published . Updated .
Key takeaways
- 8-K - Spyre Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: SYRE
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Spyre Therapeutics filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- SYRE Spyre Therapeutics+4.9% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Spyre Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and is a peer of Spyre Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson is a peer of Spyre Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+8.9% 30d
AbbVie is a peer of Spyre Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.3% 18d
Merck is a peer of Spyre Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+8.1% 30d
Abbott Laboratories is a peer of Spyre Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SYRE | +0.40% | -2.76% | base | after close | after close | after close | after close |
| XLV | -2.42% | +0.36% | base | after close | after close | after close | after close |
| LLY | -8.25% | +0.73% | base | after close | after close | after close | after close |
| JNJ | +2.19% | +2.93% | base | after close | after close | after close | after close |
| ABBV | +0.42% | +3.41% | base | after close | after close | after close | after close |
| MRK | -1.72% | +4.16% | base | after close | after close | after close | after close |
| ABT | -5.79% | -2.52% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001636282-26-000132 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Spyre Therapeutics (SYRE) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +3.41% | final price |
| ABBV | five days earlier | +0.42% | final price |
| ABT | three days earlier | -2.52% | final price |
| ABT | five days earlier | -5.79% | final price |
| JNJ | three days earlier | +2.93% | final price |
| JNJ | five days earlier | +2.19% | final price |
| LLY | three days earlier | +0.73% | final price |
| LLY | five days earlier | -8.25% | final price |
| MRK | three days earlier | +4.16% | final price |
| MRK | five days earlier | -1.72% | final price |
| Spyre Therapeutics (SYRE) | three days earlier | -2.76% | final price |
| Spyre Therapeutics (SYRE) | five days earlier | +0.40% | final price |
| XLV | three days earlier | +0.36% | final price |
| XLV | five days earlier | -2.42% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 50 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 32 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 46 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 47 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Spyre Therapeutics (SYRE)
Companies mentioned with this story
- SYRE Spyre Therapeutics
Spyre Therapeutics (SYRE) is linked, with no stored direction, high confidence in the 3 Nov 2026 story “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> SYRE
How “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)” reaches Spyre Therapeutics (SYRE)
Spyre Therapeutics (SYRE) is the company in “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer),” the 3 Nov 2026 this story story.
Spyre Therapeutics (SYRE) is on the page because SEC 8-K filing -> direct issuer disclosure -> SYRE
Price levels for Spyre Therapeutics (SYRE)
SYRE traded between 77.09 and 100.61 across 19 sessions. The latest close on file is 95.52.
How solid “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)” looks
14 out of 100
“8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.